{"id":42527,"date":"2025-09-30T14:03:57","date_gmt":"2025-09-30T06:03:57","guid":{"rendered":"https:\/\/flcube.com\/?p=42527"},"modified":"2025-09-30T14:03:57","modified_gmt":"2025-09-30T06:03:57","slug":"simnova-secures-fda-ind-for-car%e2%80%91nk-therapy-in-sle","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42527","title":{"rendered":"Simnova Secures FDA IND for CAR\u2011NK Therapy in SLE"},"content":{"rendered":"\n<p><strong>Shanghai Simnova Biotech Co., Ltd.<\/strong> (Simnova) announced that its <strong>CD19\u2011targeted chimeric antigen receptor gene\u2011modified natural killer (CAR\u2011NK) cell injection<\/strong> has received <strong>Investigational New Drug (IND) approval<\/strong> from the <strong>U.S. Food and Drug Administration (FDA)<\/strong> for the treatment of <strong>moderate\u2011to\u2011severe systemic lupus erythematosus (SLE)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-about-the-car-nk-product\">About the CAR\u2011NK Product<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Off\u2011the\u2011Shelf, All\u2011ogeneic Platform<\/strong> \u2013 The therapy uses genetically engineered natural killer cells that target CD19\u2011expressing B cells, providing a rapid, ready\u2011to\u2011use treatment option.<\/li>\n\n\n\n<li><strong>Prior Chinese Clinical Success<\/strong> \u2013 The product had already entered clinical trials in China, demonstrating profound B\u2011cell depletion and disease control in early\u2011stage studies.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investigator-initiated-trial-highlights\">Investigator\u2011Initiated Trial Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Collaboration<\/strong> \u2013 The <strong>IIT project<\/strong> partners Simnova with <strong>Shanghai Renji Hospital<\/strong> to evaluate multiple dosing regimens in SLE patients.<\/li>\n\n\n\n<li><strong>Rapid B\u2011Cell Depletion<\/strong> \u2013 All treated patients saw significant peripheral B\u2011cell loss within 4\u202fweeks, with gradual repopulation over 3\u20136\u202fmonths.<\/li>\n\n\n\n<li><strong>Clinical Efficacy<\/strong> \u2013<\/li>\n\n\n\n<li><strong>100\u202f% achieved SLE Responder Index\u20114 (SRI\u20114)<\/strong> at 1\u2011month and maintained the response.<\/li>\n\n\n\n<li><strong>60\u202f% entered Lupus Low Disease Activity State (LLDAS)\/DORIS remission<\/strong> within 3\u202fmonths.<\/li>\n\n\n\n<li><strong>Safety Profile<\/strong> \u2013 No serious adverse events such as cytokine release syndrome, neurotoxicity, or infections were observed; long\u2011term immunosuppression concerns were not raised.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011In\u2011Class U.S. IND<\/strong> \u2013 The FDA approval positions Simnova as a pioneer in gene\u2011modified NK\u2011cell therapeutics for autoimmune disease in the United States.<\/li>\n\n\n\n<li><strong>Commercial Potential<\/strong> \u2013 The platform\u2019s off\u2011the\u2011Shelf nature could lower manufacturing costs and accelerate market access compared to autologous CAR\u2011T therapies.<\/li>\n\n\n\n<li><strong>Future Expansion<\/strong> \u2013 Positive safety and efficacy data may support broader IND submissions for other autoimmune indications and facilitate global regulatory approvals.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Simnova Biotech Co., Ltd. (Simnova) announced that its CD19\u2011targeted chimeric antigen receptor gene\u2011modified natural&#8230;<\/p>\n","protected":false},"author":1,"featured_media":42529,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[77,62,3260],"class_list":["post-42527","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cell-therapy","tag-clinical-trial-approval-initiation","tag-simnova-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Simnova Secures FDA IND for CAR\u2011NK Therapy in SLE - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Simnova Biotech Co., Ltd. (Simnova) announced that its CD19\u2011targeted chimeric antigen receptor gene\u2011modified natural killer (CAR\u2011NK) cell injection has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of moderate\u2011to\u2011severe systemic lupus erythematosus (SLE).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=42527\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Simnova Secures FDA IND for CAR\u2011NK Therapy in SLE\" \/>\n<meta property=\"og:description\" content=\"Shanghai Simnova Biotech Co., Ltd. (Simnova) announced that its CD19\u2011targeted chimeric antigen receptor gene\u2011modified natural killer (CAR\u2011NK) cell injection has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of moderate\u2011to\u2011severe systemic lupus erythematosus (SLE).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=42527\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-30T06:03:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/3001.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42527#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42527\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Simnova Secures FDA IND for CAR\u2011NK Therapy in SLE\",\"datePublished\":\"2025-09-30T06:03:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42527\"},\"wordCount\":283,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42527#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/3001.webp\",\"keywords\":[\"Cell-therapy\",\"Clinical trial approval \\\/ initiation\",\"Simnova Biotech\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42527#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42527\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=42527\",\"name\":\"Simnova Secures FDA IND for CAR\u2011NK Therapy in SLE - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42527#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42527#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/3001.webp\",\"datePublished\":\"2025-09-30T06:03:57+00:00\",\"description\":\"Shanghai Simnova Biotech Co., Ltd. (Simnova) announced that its CD19\u2011targeted chimeric antigen receptor gene\u2011modified natural killer (CAR\u2011NK) cell injection has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of moderate\u2011to\u2011severe systemic lupus erythematosus (SLE).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42527#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42527\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42527#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/3001.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/3001.webp\",\"width\":1080,\"height\":608,\"caption\":\"Simnova Secures FDA IND for CAR\u2011NK Therapy in SLE\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42527#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Simnova Secures FDA IND for CAR\u2011NK Therapy in SLE\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Simnova Secures FDA IND for CAR\u2011NK Therapy in SLE - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Simnova Biotech Co., Ltd. (Simnova) announced that its CD19\u2011targeted chimeric antigen receptor gene\u2011modified natural killer (CAR\u2011NK) cell injection has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of moderate\u2011to\u2011severe systemic lupus erythematosus (SLE).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=42527","og_locale":"en_US","og_type":"article","og_title":"Simnova Secures FDA IND for CAR\u2011NK Therapy in SLE","og_description":"Shanghai Simnova Biotech Co., Ltd. (Simnova) announced that its CD19\u2011targeted chimeric antigen receptor gene\u2011modified natural killer (CAR\u2011NK) cell injection has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of moderate\u2011to\u2011severe systemic lupus erythematosus (SLE).","og_url":"https:\/\/flcube.com\/?p=42527","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-30T06:03:57+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/3001.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=42527#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=42527"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Simnova Secures FDA IND for CAR\u2011NK Therapy in SLE","datePublished":"2025-09-30T06:03:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=42527"},"wordCount":283,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=42527#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/3001.webp","keywords":["Cell-therapy","Clinical trial approval \/ initiation","Simnova Biotech"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=42527#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=42527","url":"https:\/\/flcube.com\/?p=42527","name":"Simnova Secures FDA IND for CAR\u2011NK Therapy in SLE - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=42527#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=42527#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/3001.webp","datePublished":"2025-09-30T06:03:57+00:00","description":"Shanghai Simnova Biotech Co., Ltd. (Simnova) announced that its CD19\u2011targeted chimeric antigen receptor gene\u2011modified natural killer (CAR\u2011NK) cell injection has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of moderate\u2011to\u2011severe systemic lupus erythematosus (SLE).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=42527#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=42527"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=42527#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/3001.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/3001.webp","width":1080,"height":608,"caption":"Simnova Secures FDA IND for CAR\u2011NK Therapy in SLE"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=42527#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Simnova Secures FDA IND for CAR\u2011NK Therapy in SLE"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/3001.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42527"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42527\/revisions"}],"predecessor-version":[{"id":42530,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42527\/revisions\/42530"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/42529"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}